Semaglutide for Infertility Related to Obesity

How Semaglutide Helps with Infertility Related to Obesity

Semaglutide mimics the GLP-1 hormone to reduce appetite and slow stomach emptying, leading to significant weight loss. For patients with infertility related to obesity, this weight loss translates to meaningful improvements in condition-specific outcomes.

GLP-1 weight loss restores hormonal balance, improves ovulation regularity in women, and improves sperm parameters in men, increasing chances of conception. The STEP clinical trial program demonstrated that semaglutide 2.4mg weekly produces an average weight loss of 15% of body weight over 68 weeks, with additional benefits for metabolic health markers.

Clinical Evidence for Infertility Related to Obesity

Infertility Related to Obesity affects obesity is a contributing factor in approximately 25% of infertility cases. Research shows that GLP-1 medications like semaglutide address both the weight component and the underlying metabolic dysfunction associated with infertility related to obesity. Patients with this condition often see compounding benefits from weight loss, including improved energy, mobility, and overall quality of life.

Semaglutide Dosing for Infertility Related to Obesity

Semaglutide is taken as a once-weekly subcutaneous injection. The standard titration starts at 0.25mg and gradually increases to the maintenance dose of 2.4mg over 16-20 weeks. Dosing is the same regardless of the indication — your provider will monitor your response and adjust timing as needed.

Cost of Semaglutide for Infertility Related to Obesity

Compounded semaglutide costs $149-399/month through telehealth providers. Brand-name Wegovy costs $1,300+/month without insurance. Many patients with infertility related to obesity have associated comorbidities that improve insurance coverage chances.